CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ARTiDe project focuses on developing a novel therapy for Type 1 diabetes by engineering regulatory T cells to express specific receptors that target the autoimmune response. This approach aims to restore immune tolerance and protect insulin-producing cells, ultimately improving treatment outcomes for patients.
Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, and high social burden.
It is caused by the autoimmune destruction of insulin-producing beta cells, yet the standard of care is insulin replacement, acting only at the symptom level.
Thus, T1D is a disease with a high unmet need for innovative therapy.
Ideally, such therapy shall suppress selectively the immune cells driving T1D without impairing protective i…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, PARIS
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Paris
Type: Research institute
Activity type: Research Organisations
SME: No
Poland, GDANSK
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
